Available online and in the upcoming June print issue of MIMS, the table helps prescribers quickly compare GLP-1 agonists for the treatment of type II diabetes.
The table covers dosing frequency, cost per 28 days, suitability for monotherapy, and possible treatment combinations with metformin, pioglitazone, sulfonylureas, SGLT2 inhibitors and insulin. Cardiovascular benefits, including positive effects on blood pressure and adverse cardiovascular events, are also noted.
Information is provided for all available GLP-1 agonists: dulaglutide (Trulicity), exenatide (Bydureon and Byetta), liraglutide (Victoza), lixisenatide (Lyxumia), and semaglutide (Ozempic).
All information is taken from the manufacturers' summaries of product characteristics.
MIMS also provides a visual guide to prefilled GLP-1 pens and a table summarising dose adjustments for GLP-1 agonists and other antidiabetic drugs in patients with renal impairment.